Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

FDA Cautions Slower Drug Review Activity Due to Staff Reallocation for COVID-19

Reuters Staff  |  

(Reuters)—On April 16, the U.S. Food & Drug Administration (FDA) cautioned that with a lot of its staff allocated to the coronavirus crisis, it may not be able to sustain its current level of timely reviews and approvals of marketing applications.

FDA says it was working to ensure that the drug programs continue to see minimal interruptions during this time. But if there was an increase in drugs shortages and supply disruptions, it will be ready to reprioritize its work.¹

ADVERTISEMENT
SCROLL TO CONTINUE

The agency says its staff was working at full capacity to ensure that safe and effective drugs and biologics are available to the public, and are continuing to meet review goals, approve applications and communicate with drug developers.

Reporting By Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli

ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA continues user-fee related reviews through COVID-19. PR Newswire. 2020 Apr 16.

Related Articles

    Vax Hesitancy? Myths & Facts for Patients

    Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S. counties—particularly in the Southeast…

    Enemy at the Gates: The Emerging Threat of COVID-19

    On Dec. 30, 2019, an ophthalmologist named Li Wenliang notified his colleagues about an illness that was reminiscent of severe acute respiratory syndrome (SARS) in a city in the Hubei province of China called Wuhan. As an ophthalmologist, this was not directly relevant to his practice; he merely wanted to warn colleagues that they might…

    Serological Antibody Tests in COVID-19: Test Reliability and Utility

    Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may play a critical role in the management of the worldwide health crisis. Such testing may reveal key information for epidemiology, convalescent plasma therapies and vaccine development. However, the situation is complex, and much is unknown. Although such testing may ultimately be used to…

    Corona Borealis Studio / shutterstock.com

    The Reliability & Utility of Serological Antibody Tests in COVID-19

    Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may play a critical role in the management of the worldwide health crisis. Such testing may reveal key information for epidemiology, convalescent plasma therapies and vaccine development. However, the situation is complex, and much is unknown. Although such testing may ultimately be used to…